Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Evaluation of different approaches for establishing an in-vitro/in-vivo correlation for a BCS class IV molecule case study: Candesartan Cilexetil tablets

  • At: 2016 FIP Congress in Buenos Aires (Argentina)
  • Type: Poster
  • By: FíGOLI, Gustavo (Phoenix, Buenos Aires, Argentina)
  • Co-author(s): Gustavo Fígoli:Development Department,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|Fernando Montini:Development Department,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|Daniel Goicochea:Development Department,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|Florencia De Blasiis:Development Department,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|Silvana Quattrocchi:Development Department,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|James Butler:Biopharmaceutics, Product Development,GSK,Ware,United Kingdom|Florencia Esquivel:Medical Department ,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|Alejandro Di Cio Gimena:Medical Department,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|Cristian Oddo:Development Department,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|Rajesh Patel:Classic and Established Products,GSK,London,United Kingdom
  • Abstract:

    IVIVC supports Oral Solid Dose optimization and could help to reduce the amount of in-vivo trials in humans, fixes dissolution acceptance criteria, and can be used as a surrogate for further bioequivalence studies. Candesartan cilexetil a BCS Class IV was used for this study.

    Different formulations of candesartan cilexetil and candesartan cilexetil

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses